Drugs in search of LTR with right protein

Chemical & Engineering News gives us a lesson in the joys of covalent bonds. Apparently, they're the marrying type, forming irreversible, 'til-death-do-us-part bonds between small-molecule drugs and protein targets. The fear is that a covalent bond would be "so desperate for a mate" that it hitches up to the wrong target, causing toxic side effects. As a result, drug companies have been happy to produce drugs that just can't commit. Now, groups of scientists within academia and in pharmaceutical companies are working on drugs that are looking for a long-term relationship with a single target and are working on covalent drug candidates. The strategy could mean drugs with low toxicity and high potency and selectivity. Full report here

Suggested Articles

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.

GigaGen joined a group of companies making plasma-based, polyclonal antibody treatments for COVID-19.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.